Melanoma Clinical Trials in San Antonio

Showing 161-180 of 203 trials

Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma

NCT00387751

This phase II trial is studying how well giving bevacizumab together with sorafenib works in treating patients with unresectable stage III or stage IV malignant melanoma. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab and sorafenib may also stop the growth of melanoma by blocking blood flow to the tumor. Giving bevacizumab together with sorafenib may kill more tumor cells.

Recurrent MelanomaStage III Skin MelanomaStage IV Skin Melanoma

National Cancer Institute (NCI)14 participantsStarted Aug 2006

San Antonio, Texas, United States

COMPLETEDPhase 2< 1 mile

Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma

NCT00110994

This is a randomized, double blind, placebo controlled, multicenter, phase II study to compare the anti-tumor activity as measured by progression-free survival (PFS) and the tolerability of Sorafenib in combination with Dacarbazine (DTIC) versus DTIC in combination with placebo in subjects with unresectable Stage III or Stage IV melanoma who have not received prior cytotoxic chemotherapy. A total of approximately 98 subjects will be randomized to receive DTIC + Sorafenib or DTIC + Placebo.

CancerMelanoma

Bayer101 participantsStarted Apr 2005

Tucson, Arizona, United States • Aurora, Colorado, United States • Lakeland, Florida, United States +11 more locations

Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma

Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma

Melanoma Trials in Other Cities

Safety Study of PLX4032 in Patients With Solid Tumors

Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma

Phase II, 2nd Line Melanoma - RAND Monotherapy

Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation

A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma

A Study of Vemurafenib in Participants With Metastatic Melanoma

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)

Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma

Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma

Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma

Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye

Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients

Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma

Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Other Conditions in San Antonio